179 related articles for article (PubMed ID: 36840956)
21. Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.
Cranmer H; Trueman D; Evers E; Woodcock F; Podkonjak T
Pharmacoecon Open; 2022 Nov; 6(6):881-892. PubMed ID: 36057890
[TBL] [Abstract][Full Text] [Related]
22. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
Ngu HS; Savage KJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
[TBL] [Abstract][Full Text] [Related]
23. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
[No Abstract] [Full Text] [Related]
24. [Current treatment strategies for peripheral T-cell lymphoma].
Munakata W
Rinsho Ketsueki; 2021; 62(8):1112-1120. PubMed ID: 34497198
[TBL] [Abstract][Full Text] [Related]
25. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
[TBL] [Abstract][Full Text] [Related]
27. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
Liang X; Guo L; Hu X; Li S; Wen S
Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
[TBL] [Abstract][Full Text] [Related]
28. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
Ngu HS; Savage KJ
Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
31. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
[No Abstract] [Full Text] [Related]
32. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
Kim JG; Sohn SK; Chae YS; Kim DH; Baek JH; Lee KB; Lee JJ; Chung IJ; Kim HJ; Yang DH; Lee WS; Joo YD; Sohn CH
Cancer Chemother Pharmacol; 2006 Jul; 58(1):35-9. PubMed ID: 16308699
[TBL] [Abstract][Full Text] [Related]
33. Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population.
Shirouchi Y; Yokoyama M; Fukuta T; Uryu H; Nishimura N; Mishima Y; Inoue N; Tsuyama N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Aug; 62(8):1869-1876. PubMed ID: 33688781
[TBL] [Abstract][Full Text] [Related]
34. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
Phillips T; Migliaccio-Walle K; Yu KS; Bloudek B; Liu N; Fanale M; Burke JM
Leuk Lymphoma; 2023 May; 64(5):1017-1025. PubMed ID: 37074674
[TBL] [Abstract][Full Text] [Related]
35. ECHELON-2 - brentuximab raises PTCL outcomes to new levels.
Killock D
Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30602757
[No Abstract] [Full Text] [Related]
36. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
37. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
Jia B; Hu S; Yang J; Zhou S; Liu P; Qin Y; Gui L; Yang S; Lin H; Zhang C; Xing P; Wang L; Dong M; Zhou L; Sun Y; He X; Shi Y
Hematology; 2016 Oct; 21(9):536-41. PubMed ID: 27077778
[TBL] [Abstract][Full Text] [Related]
38. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
[TBL] [Abstract][Full Text] [Related]
39. Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
Akagi T; Takahashi N; Yamaguchi K; Ishizawa K; Murai K; Tajima K; Ikeda K; Kameoka Y; Kameoka J; Ito S; Kato Y; Noji H; Shichishima T; Itoh J; Ichinohasama R; Harigae H; Ishida Y; Sawada K
J Clin Exp Hematop; 2011; 51(1):29-35. PubMed ID: 21628858
[TBL] [Abstract][Full Text] [Related]
40. NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
Kriachok I; Tytorenko I; Shudrak N; Aleksik O; Stepanishyna Y; Kadnikova T; Pastushenko Y; Shokun N; Rudiyk T; Bushuieva M
Exp Oncol; 2024 Feb; 45(4):474-482. PubMed ID: 38328842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
